View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Lynn Hautekeete
  • Lynn Hautekeete

Aedifica Belgian competitive authorities might delay merger timeline

Aedifica gives an update on the approval of the Belgian competitive authorities in regards to the Cofinimmo merger. The Belgian authorities have asked additional information which might delay the timeline of the transaction. As a reminder the acceptance period was to open in September with the EGM to vote on a merger in October (depending on the 51.0% thresholds during the acceptance period). The Dutch/German authorities have already give approval. There is no further information on what details...

Hilde Van Boxstael ... (+3)
  • Hilde Van Boxstael
  • Michiel Declercq
  • Wim Hoste
 PRESS RELEASE

Aedifica NV/SA – Update on the progress of Aedifica’s and Cofinimmo’s ...

Aedifica NV/SA – Update on the progress of Aedifica’s and Cofinimmo’s case with the Belgian Competition Authority More information is available on Aedifica’s website via the link below and can be accessed subject to the usual restrictions.

Hilde Van Boxstael ... (+6)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Livio Luyten
  • Michiel Declercq
  • Thomas Vranken
  • Wim Hoste
Jacob Mekhael ... (+2)
  • Jacob Mekhael
  • Thomas Vranken

Pharvaris FIRST LOOK: Accelerated timelines for on-demand HAE treatmen...

Pharvaris has accelerated its timeline for topline data from the RAPIDe-3 Phase 3 trial evaluating deucrictibant for on-demand treatment of hereditary angioedema (HAE), now expected in 4Q25 instead of 1Q26. The study aims to confirm earlier Phase 2 findings and measures time to symptom relief. Pending positive results, Pharvaris plans to submit its FDA application in the first half of 2026. Meanwhile, the company is also advancing its prophylactic HAE program and planning studies in acquired ang...

 PRESS RELEASE

Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Piv...

Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025 Company expects to submit deucrictibant IR capsule NDA to the U.S. FDA for the on-demand treatment of HAE attacks in 1H2026 ZUG, Switzerland, July 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), updated...

Dylan Shindler ... (+2)
  • Dylan Shindler
  • Laura Chico
Roy Külter ... (+2)
  • Roy Külter
  • Thomas Zlowodzki
Roy Külter ... (+2)
  • Roy Külter
  • Thomas Zlowodzki
 PRESS RELEASE

Aedifica NV/SA: Publication relating to a transparency notification

Aedifica NV/SA: Publication relating to a transparency notification Please find below a press release from Aedifica (a public regulated real estate company under Belgian law, listed on Euronext Brussels and Euronext Amsterdam), regarding a publication relating to a transparency notification. Attachments

Hilde Van Boxstael ... (+4)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Lynn Hautekeete
  • Michiel Declercq
Jacob Mekhael
  • Jacob Mekhael

MaaT Pharma Partnership with Clinigen secures MaaT013's EU commerciali...

MaaT signed a licensing, distribution, and commercial supply agreement with Clinigen in Europe for Xervyteg (MaaT013, microbiome therapy, enema formulation) in aGvHD for a € 10.5m upfront, € 18m in milestones, and mid-thirties flat royalty on sales. We believe this deal serves as validation of MaaT013's potential, and see the partnership as a de-risking event for MaaT013's commercialisation in Europe, given Clinigen's experience commercialising in haemato-oncology, with 3 products currently on t...

Delphine Brault ... (+2)
  • Delphine Brault
  • Steven Boumans
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch